Novartis’s Kesimpta Already A Big Earner But Leqvio Is Slow Burner
MS Drug Selling Strongly In US
Novartis’s multiple sclerosis treatment Kesimpta has shot out of the gates and bidding fair to contribute generously to the firm’s coffers, while new cholesterol drug Leqvio struggles, Q1 results show.
